Leaflet XATRAL SR 10mg prolonged-release tablets


Indicated for: benign prostatic hyperplasia

Substance: alfuzosin (alpha-1 blocker)

ATC: G04CA01 (Genito urinary system and sex hormones | Drugs used in benign prostatic hypertrophy | Alpha-adrenoreceptor antagonists)

Alfuzosin is a medication used to treat symptoms associated with benign prostatic hyperplasia (BPH), a condition characterized by an enlarged prostate that can cause difficulty urinating. Alfuzosin belongs to the class of alpha-blockers and works by relaxing the smooth muscles in the prostate and bladder neck, making it easier to urinate.

It is taken orally, usually once daily after a meal, to reduce the risk of side effects. Beneficial effects may be noticed within a few days of starting treatment.

Common side effects include dizziness, fatigue, headache, or orthostatic hypotension (a drop in blood pressure when standing up). Patients are advised to avoid sudden movements to prevent dizziness. Alfuzosin is contraindicated in patients with severe liver impairment or those taking other medications that may interact with it. It should be used as directed by a doctor.

General data about XATRAL SR 10mg

  • Substance: alfuzosin
  • Date of last drug list: 01-05-2026
  • Commercial code: W62086003
  • Concentration: 10mg
  • Pharmaceutical form: prolonged-release tablets
  • Quantity: 30
  • Product type: original
  • Price: 41.68 RON
  • Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Marketing authorisation

  • Manufacturer: SANOFI WINTHROP INDUSTRIE - FRANTA
  • Holder: SANOFI ROMANIA S.R.L. - ROMANIA
  • Number: 11628/2019/02
  • Shelf life: 3 years

Concentrations available for alfuzosin

  • 10mg
  • 2.5mg
  • 5mg

Compensation lists for XATRAL SR 10mg Sanofi

B - Sublist B with 50% discount from the reference price

Price

Copayment

Patient

41.68 RON

20.84 RON

20.84 RON